Latest Advances in Lung Cancer Research

Studies show smoking marijuana may harm lungs but lacks strong evidence linking it to lung cancer; research is challenged by marijuana’s legal history and variability.

Memorial Sloan Kettering researchers find a new SCLC subtype with normal Rb protein, potentially treatable with existing CDK4/6 inhibitor drugs.

Study shows nearly half of high-risk lung cancer screenings have delayed follow-up, with current smokers at higher risk of delays in care.

Global lung cancer rates have risen over 30 years with significant regional variations; researchers urge tailored interventions to address this persisting major health issue.

Opdivo plus chemo reduces death risk by 43% pre-surgery in NSCLC patients, leading to FDA approval, with broad patient eligibility regardless of PD-L1 levels.

Study finds White Americans 50% more likely to receive lung cancer screenings than Black Americans; health perception influences screening likelihood.

Merck’s Keytruda reduces early-stage lung cancer recurrence by 24% post-surgery, with plans for FDA approval submission, and shows a favorable safety profile.

Canadian researchers developed IPRO, a deep learning model for lung cancer care, enhancing prognosis by analyzing pre-treatment CT scans without manual input.

The FDA rapidly approved Bristol Myers Squibb’s Opdivo for early-stage NSCLC, marking a major advancement in pre-surgical cancer treatment.

FDA skepticism challenges sintilimab’s approval for NSCLC, citing concerns over trial data exclusivity from China and its less favored endpoint of PFS.